Press release from Companies

Publicerat: 2023-01-19 16:40:37

Calmark Sweden AB: The distributor agreement for Saudi Arabia with Ajlan & Bros is terminated

Calmark Sweden AB (publ) announced today that the exclusive distributor agreement for the Saudi Arabian market with the company Ajlan & Bros Holding Group Abilitii will not continue.

The agreement was signed on August 9, 2022, and an initial order was received a month later on September 8. Ajlan Bros is undergoing organizational changes which means that Calmarks launch has not received the desired focus. The agreement is therefore terminated by mutual decision.

The search for a new distributor for Saudi Arabia has started.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-01-2023 16:40 CET.

For more information about Calmark Sweden AB, please contact:

Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50

E-post: camilla.arneving@calmark.se

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  

Läs mer hos Cision
Läs mer om Calmark Sweden AB